4P Therapeutics-Novel Transdermal Delivery Systems for Treatment of Diabetes

News & Press: Industry News

4P Therapeutics-Novel Transdermal Delivery Systems for Treatment of Diabetes

Tuesday, May 13, 2014 (0 Comments)
Posted by: Maria Thacker

Share |

In the context of a diabetes epidemic, which he characterises in terms of incidence, prevalence and healthcare costs, Alan Smith, PhD, Vice-President, Clinical, Regulatory & Operations, 4P Therapeutics, outlines the stages of Type 2 diabetes treatment, progressing to extenatide and insulin injections, and makes the case, using clinical data, for the transdermal route as a viable alternative to injections.

Read the complete publication at: http://www.ondrugdelivery.com/publications/49/4P.pdf